Angiodroid
Angiodroid S.p.A. is an Italian medtech company that develops and sells a patented automated CO2 injector and related consumables for peripheral angiography, serving interventional radiology, vascular surgery, and cardiology departments in 500+ hospitals across 55+ countries.
- Company typePrivate
- Founded2015
- HeadquartersSan Lazzaro, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Angiodroid does
Angiodroid S.p.A. is an Italy-based medical device company (headquartered in San Lazzaro di Savena, Bologna) that develops and commercializes a patented, fully automatic injector for delivering medical-grade carbon dioxide (CO2) as a contrast agent in peripheral angiography procedures. The core system, branded "Angiodroid The CO2 Injector," provides precise volume and pressure control through a one-way valve architecture that prevents air contamination, with a touchscreen interface, wireless remote control (reducing operator X-ray exposure), built-in pressure monitoring, and arc-synchronization compatibility with the angiography systems of Philips, Siemens Healthineers, and Ziehm Imaging. The company complements the capital device with recurring consumable revenue from proprietary Single Use Adaptors and Procedural Kits.
The business model is a medical device hardware-plus-consumables sale into hospital interventional radiology, vascular surgery, and interventional cardiology departments, with particular clinical positioning for patients with renal impairment, iodine allergies, or diabetes for whom iodinated contrast poses elevated risk. Angiodroid has commercialized its products in 55+ countries, served 500+ hospitals, and obtained 32 international certifications in addition to CE marking (with KFDA for South Korea and ANVISA for Brazil specifically named). Distribution combines direct hospital sales with channel partners in selected markets (BERTZ MEDICAL in Poland, Proendo in Brazil, Allex Medical System in India).
The company is privately held, was founded in 2013 (incorporated 2015), transitioned from Srl to S.p.A. in 2023, and is led by founder-CEO Sebastiano Zannoli with Lorenzo Casadei as product development manager. In February 2023, Angiodroid closed a €7 million Series A financing round led by CDP Venture Capital (with 8a+ Investments SGR and strategic investor Air Liquide ALIAD) earmarked for international expansion and commercial partnerships. Recent product and clinical milestones include the world-first CO2 3D imaging (CBCT) protocol at University Hospital of Padua in December 2025 and policy-level engagements at the Italian and French Senates in 2025-2026. The US market, representing over 35% of the global opportunity, is identified as the next strategic expansion target but US FDA clearance is not yet confirmed.
Angiodroid firmographics
Firmographics- Name
- Angiodroid
- Legal name
- Angiodroid S.p.A.
- Website
- https://angiodroid.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Angiodroid S.p.A. is an Italian medtech company that develops and sells a patented automated CO2 injector and related consumables for peripheral angiography, serving interventional radiology, vascular surgery, and cardiology departments in 500+ hospitals across 55+ countries.
- Ownership category
- akta.pro rank
Angiodroid industry classification
Industry- Product category
- Medical Devices — Interventional Angiography Equipment
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Contrast Media Injectors & Radiology Accessories (HLAHABAK)
Keywords
Where Angiodroid is headquartered
LocationHeadquarters
- HQ city
- San Lazzaro
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Angiodroid business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Angiodroid generates revenue primarily through the sale of its CO2 injector devices and related disposable products (Single Use Adaptor and Procedural Kit). The company sells directly to hospitals and through distribution partners in international markets.
- Disposable Products: Recurring revenue from consumable disposable products including Single Use Adaptor for connecting the CO2 Injector to catheters and Angiodroid Procedural Kit for device-catheter connection and surface protection.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Angiodroid product offering
Product offeringCore offering
Angiodroid manufactures and sells a patented automated CO2 injector device for peripheral angiography that uses medical-grade carbon dioxide as a contrast agent alternative to iodinated contrast media. The core system is a hardware injector with touchscreen interface, wireless remote control, integrated pressure monitoring, and arc-synchronization compatibility with Philips, Siemens, and Ziehm angiography systems. The company also sells recurring disposable consumables (Single Use Adaptor and Procedural Kit) used with each procedure.
Product overview
Angiodroid offers a focused portfolio of medical devices centered on automated CO2 angiography technology. The core offering is the Angiodroid The CO2 Injector, a patented automated device for peripheral angiography that uses medical CO2 as a contrast agent instead of iodine-based media. This main device is supported by disposable consumables including the Single Use Adaptor and Procedural Kit. The product line includes arc-synchronization capability for integration with major angiography systems (Philips, Siemens, Ziehm). The company is also developing Angiopulse as an upcoming product. Angiodroid operates from Italy and has commercialized its products in over 55 countries.
Differentiator
Problem solved
Functional benefit
Products and services
- Angiodroid The CO2 Injector
Quantifiable outcome
- Estimated 300 Angio-CT exams avoided per year at University Hospital of Padua due to improved intraoperative imaging accuracy
- +1 more outcomes
Companies that use Angiodroid
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles3 records
Angiodroid technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature7 records
Angiodroid partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- BERTZ MEDICALcoreExclusive distribution partner for Poland providing distribution and servicing of medical devices. BERTZ MEDICAL is a dynamically developing company focused on maintaining highest standards of offer and customer service with experienced team providing professional customer service and warranty and post-warranty service.
- ProendocoreLocal distribution partner in Brazil for the CICE (Congresso Internacional de Cirurgia Endovascular) event and ongoing market development following ANVISA certification.
- Allex Medical SystemminorDistribution support partner in India that facilitated the first Angiodroid case at Rajiv Gandhi Cancer Hospital in New Delhi.
- Siemens HealthineerscoreTechnology integration partnership for CO2 angiography protocols. Angiodroid's injector is included in Siemens Healthcare booth at events and supports new CO2 protocol development for Siemens angiography systems.
- Philips HealthcarecoreArc-synchronization capability compatibility with Philips angiography systems (Artis, Azurion) enabling seamless integration into clinical workflows.
- Ziehm ImagingcoreArc-synchronization compatibility with Ziehm Angiosystems enabling integration with Ziehm mobile C-arms for hybrid operating room setups.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
Angiodroid competitors and assessment
Company assessmentBroad incumbents
- Merit Medical Systems: Merit Medical is a broad interventional and diagnostic medical device company with products spanning angiography, vascular intervention, and procedural accessories. Comparable as a diversified incumbent in the interventional radiology procedural ecosystem in which Angiodroid's CO2 injector is used.
- Guerbet: Guerbet is a global specialty contrast media and injector company serving interventional radiology and cardiology. It is comparable to Angiodroid as a participant in the angiography contrast-injection value chain, with a broader but largely iodinated-contrast portfolio.
- GE HealthCare: GE HealthCare is one of the dominant angiography imaging OEMs alongside Philips and Siemens — the same group Angiodroid has integrated with via arc-synchronization. Comparable as a broad incumbent shaping clinical workflows and potentially developing or acquiring CO2-injection capabilities.
- Bracco Imaging: Bracco is a global contrast media and injector company (including ACIST cardiovascular injection systems). It is a broad incumbent in the same contrast-injection space where Angiodroid operates, though Bracco's portfolio is dominated by iodinated agents while Angiodroid focuses on CO2.
- Bayer (Medrad): Bayer's Radiology business includes Medrad, the global leader in power contrast injectors for CT, MR, and angiography. Angiodroid competes in the contrast-injection category but targets the narrower, iodine-free CO2 angiography niche rather than Bayer's iodinated-contrast dominated franchise.
Emerging players
- AngioDynamics: AngioDynamics is a US-based developer and manufacturer of minimally invasive peripheral vascular and interventional radiology devices. Comparable as an emerging player addressing the same vascular/interventional radiology clinical customers and procedures that Angiodroid's CO2 injector supports.
- Penumbra: Penumbra is a US-based interventional vascular thrombectomy and embolization company serving interventional radiologists and vascular surgeons. Comparable as a peer operating in the same interventional procedural suites and customer base where Angiodroid's CO2 angiography is used.
Direct peers
- Optimed: Optimed is a German manufacturer of manual CO2 injectors for angiography, the closest direct functional peer to Angiodroid. Both target the same clinical use case (CO2 as contrast agent in peripheral angiography) but Optimed's products are manual injectors while Angiodroid's are fully automatic — the core Angiodroid differentiator.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Angiodroid social profiles
Digital presenceAngiodroid compliance and trust
Trust signalCompliance4 records
Angiodroid financial estimates
Financial estimateRevenue estimate
Valuation estimate
Angiodroid leadership team
Management profileNumber of profiles
Profiles2 records
Angiodroid funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Angiodroid M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Angiodroid
What does Angiodroid do?
Angiodroid manufactures and sells a patented automated CO2 injector device for peripheral angiography that uses medical-grade carbon dioxide as a contrast agent alternative to iodinated contrast media. The core system is a hardware injector with touchscreen interface, wireless remote control, integrated pressure monitoring, and arc-synchronization compatibility with Philips, Siemens, and Ziehm angiography systems. The company also sells recurring disposable consumables (Single Use Adaptor and Procedural Kit) used with each procedure.
Is Angiodroid a public or private company?
Angiodroid is a private company. It is classified as venture growth investor backed and is currently operating.
When was Angiodroid founded?
Angiodroid was founded in 2015. It employs 11 to 50 people.
Where is Angiodroid based?
Angiodroid is headquartered in San Lazzaro, Italy, in the Europe region.
How does Angiodroid make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are disposable Products.
Who are Angiodroid's main competitors?
Broad incumbents on record are Merit Medical Systems, Guerbet, GE HealthCare, Bracco Imaging and Bayer (Medrad). Emerging players are AngioDynamics and Penumbra. Optimed is listed as a direct peer.
Does Angiodroid have an API?
No public API is recorded for Angiodroid.
What industry is Angiodroid in?
Angiodroid's product category is Medical Devices — Interventional Angiography Equipment. Its primary akta.pro industry code is HLAHABAK, Contrast Media Injectors & Radiology Accessories. Its NAICS code is 334510 and its SIC code is 3845.